Trial Profile
Multicenter, Randomized, Double-blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anemia Without the Need of Transfusion
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms SINTRA-REV
- 14 Feb 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 Final Results of Sintra-REV Phase III International Multicenter Clinical Trial presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 22 Nov 2021 Planned End Date changed from 1 Jan 2022 to 1 May 2023.